Affiliations: [a] Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China
| [b] Department of Neurobiology, Xuanwu Hospital of Capital Medical University, Key Laboratory for Neurodegenerative Diseases of the Ministry of Education, Beijing, China
| [c] Center of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, China
| [d]
National Clinical Research Center for Geriatric Disorders, Beijing, China
Correspondence:
[*]
Correspondence to: Ying Han, Department of Neurology, Xuanwu Hospital of Capital Medical University, Xicheng District, Beijing 100053, China. Tel.: +86 13621011941; E-mail: hanying@xwh.ccmu.edu.cn.
Note: [1] These authors contributed equally to this work.
Abstract: Alzheimer’s disease (AD), the main cause of dementia, is characterized by the aggregation of amyloid-β (Aβ). This pathophysiological process starts many years to decades before the onset of clinical symptoms. Cerebrospinal fluid analysis and amyloid positron emission tomography scans are two standard methods to measure brain Aβ, but their invasive nature and expense limit their usage as screening tools. Therefore, peripheral Aβ studies have grown exponentially during the past few years. In this review, we discuss recent studies on plasma Aβ and its potential as a reliable biomarker of AD.
